Tumor-associated NK Cells Regulate Distinct CD8+ T-cell Differentiation Program in Cancer and Contribute to Resistance against Immune Checkpoint Blockers
No‐Joon Song(The Ohio State University Comprehensive Cancer Center – Arthur G. James Cancer Hospital and Richard J. Solove Research Institute), Zihai Li(The Ohio State University Comprehensive Cancer Center – Arthur G. James Cancer Hospital and Richard J. Solove Research Institute), Bethany L. Mundy-Bosse(The Ohio State University Comprehensive Cancer Center – Arthur G. James Cancer Hospital and Richard J. Solove Research Institute), Jean‐Christophe Marine(VIB-KU Leuven Center for Cancer Biology), Kyeong Joo Jung(The Ohio State University Comprehensive Cancer Center – Arthur G. James Cancer Hospital and Richard J. Solove Research Institute), Parker Kronen(The Ohio State University), Yi Wang(The Ohio State University Comprehensive Cancer Center – Arthur G. James Cancer Hospital and Richard J. Solove Research Institute), Qin Ma(The Ohio State University), Jayajit Das(Nationwide Children's Hospital), Niccolò Roda(VIB-KU Leuven Center for Cancer Biology), Hyeongseon Jeon(The Ohio State University Comprehensive Cancer Center – Arthur G. James Cancer Hospital and Richard J. Solove Research Institute), Juan Xie(The Ohio State University Comprehensive Cancer Center – Arthur G. James Cancer Hospital and Richard J. Solove Research Institute), Joanna Poźniak(VIB-KU Leuven Center for Cancer Biology), Nigel Cox(Nationwide Children's Hospital), Anjun Ma(The Ohio State University Comprehensive Cancer Center – Arthur G. James Cancer Hospital and Richard J. Solove Research Institute), Nicholas Denko(Sylvester Comprehensive Cancer Center), Anqi Li(The Ohio State University Comprehensive Cancer Center – Arthur G. James Cancer Hospital and Richard J. Solove Research Institute), David P. Carbone(Vanderbilt University), William E. Carson(The Ohio State University Comprehensive Cancer Center – Arthur G. James Cancer Hospital and Richard J. Solove Research Institute), Brian Riesenberg(University of North Carolina at Chapel Hill), Darren Wethington(Nationwide Children's Hospital), Dongjun Chung(The Ohio State University Comprehensive Cancer Center – Arthur G. James Cancer Hospital and Richard J. Solove Research Institute), Kelsi Reynolds(The Ohio State University Comprehensive Cancer Center – Arthur G. James Cancer Hospital and Richard J. Solove Research Institute), Tong Xiao(The Ohio State University Comprehensive Cancer Center – Arthur G. James Cancer Hospital and Richard J. Solove Research Institute), Christin E. Burd(Cancer Genetics (United States))
Cited by 17
Related Papers
Overall Survival and Long-Term Safety of Nivolumab (Anti–Programmed Death 1 Antibody, BMS-936558, ONO-4538) in Patients With Previously Treated Advanced Non–Small-Cell Lung Cancer
|Journal of Clinical Oncology|2015|1.2k
Expansion of myeloid immune suppressor Gr+CD11b+ cells in tumor-bearing host directly promotes tumor angiogenesis
|Cancer Cell|2004|1.1k
Non-small-cell lung cancer
|Nature Reviews Disease Primers|2015|1.1k
Abrogation of TGFβ Signaling in Mammary Carcinomas Recruits Gr-1+CD11b+ Myeloid Cells that Promote Metastasis
|Cancer Cell|2008|917
Liquid Biopsy for Advanced Non-Small Cell Lung Cancer (NSCLC): A Statement Paper from the IASLC
|Journal of Thoracic Oncology|2018|661